The big news is that the Fed cut rates by 50 basis points yesterday, and the market is dramatically rising. How is your coverage space looking? Dr. Phipps: Well, admittedly, the XBI, which is the ETF ...
First please introduce your firm and your coverage. You recently said that this is a very problematic market. Why so? What prompts the change in your outlook? Dr. Brozak: I am President of WBB ...
Please provide an overview of your coverage and the subsectors, cap sizes, and primary names that you follow. Mr. Beatty: I cover biotech. And within biotech, most of my coverage is within the ...
We spoke about two years ago. How would you compare today’s market to back then? Mr. Vandermosten: Two years ago would have been fall 2022, and I think we had seen about a year of pullback in the life ...
Could you tell me about the company? Mr. Keddie: CompuMed is kind of a unique space. We’re in the telemedicine space. We started out, actually, in the early days, building echocardiogram devices, and ...
So let’s start with a brief history of the company and its mission. Mr. Pilcher: Sure. So Neuren is an interesting company, which has had a long history and a couple of incarnations. Twenty years ago ...
Please give me an overview of the company and its services. Mr. Gonen: MediWound is a global leader in next generation enzymatic therapeutics for tissue repair. Our core active pharmaceutical ...
It’s been a few years since you spoke with The Wall Street Transcript. So, let’s start with a brief overview and history of the company. Dr. Itescu: Sure. So, we’re a mature company. We’re listed on ...
Could you tell me about Premier? Mr. Alkire: Sure. Premier is a health care improvement company. We have two different segments to our business. We have a supply chain segment and a performance ...